I suggest anyone with a serious investment interest in MSB have a listen to today's presentation of the endpoint data. Excellent insight into just how rigorous the trial design was so that MSB could emerge from the trial holding the standard of care in treatment of this disease. Also some really important discussion of commercialisation and the strategy around partnering. I've updated my sentiment from hold to buy, but as always DYOR
Ann: Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial, page-62
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |